Latest Articles
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 - The Manila Times
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 …
Published: Jan. 8, 2026, 12:53 p.m.
Endometrial Protein Sparks Pre-Eclampsia and Development Issues - Bioengineer.org
Endometrial Protein Sparks Pre-Eclampsia and Development Issues Bioengineer.org
Published: Dec. 10, 2025, 11:22 a.m.
Hope Medicine Inc.'s HMI-115 Received U.S. FDA Fast Track Designation, Accelerating Global Development - The Manila Times
Hope Medicine Inc.'s HMI-115 Received U.S. FDA Fast Track Designation, Accelerating Global Development The Manila Times
Published: Dec. 4, 2025, 12:30 p.m.
Hope Medicine Inc.'s HMI-115 Received U.S. FDA Fast Track Designation, Accelerating Global Development - Laotian Times
Hope Medicine Inc.'s HMI-115 Received U.S. FDA Fast Track Designation, Accelerating Global Development Laotian Times
Published: Dec. 4, 2025, 12:08 p.m.
Hope Medicine Inc.'s HMI-115 Received U.S. FDA Fast Track Designation, Accelerating Global Development - PR Newswire
Hope Medicine Inc.'s HMI-115 Received U.S. FDA Fast Track Designation, Accelerating Global Development PR Newswire
Published: Dec. 4, 2025, 12:08 p.m.
Hope Medicine Inc.'s HMI-115 Received U.S. FDA Fast Track Designation, Accelerating Global Development - acrofan.com
Hope Medicine Inc.'s HMI-115 Received U.S. FDA Fast Track Designation, Accelerating Global Development acrofan.com
Published: Dec. 4, 2025, 11:08 a.m.
European Endometrial Ablation Market Outlook 2025-2035: Key Developments and Future Scope - openPR.com
European Endometrial Ablation Market Outlook 2025-2035: Key Developments and Future Scope openPR.com
Published: Nov. 20, 2025, 8:55 a.m.
Development of a senescence-related lncRNA signature in endometrial cancer based on multiple machine learning models - Frontiers
Development of a senescence-related lncRNA signature in endometrial cancer based on multiple machine learning models Frontiers
Published: Nov. 11, 2025, 4:15 p.m.
Early-onset uterine cancer research seeks new therapy development for younger patients - Today@Wayne
Early-onset uterine cancer research seeks new therapy development for younger patients Today@Wayne
Published: Oct. 6, 2025, 4:10 p.m.
The role of dysbiosis in shaping host immunity in endometrial cancer development - Frontiers
The role of dysbiosis in shaping host immunity in endometrial cancer development Frontiers
Published: Aug. 11, 2025, 9:50 a.m.
Link copied to clipboard!